GANX (Gain Therapeutics) Total Operating Expense: $19.70 Mil (TTM As of Mar. 2026)


GANX Gain Therapeutics Inc GANX
32 GF Score
Price $1.91
! 2 Warning Signs
View Full Analysis

What is Gain Therapeutics Total Operating Expense?

Gain Therapeutics GANX -3.78% 32 Total Operating Expense is $19.70 Mil as of Mar. 2026. GuruFocus rates GANX with a GF Score™ of 32/100. The stock has 2 warning signs investors should review.

Gain Therapeutics's Total Operating Expense for the three months ended in Mar. 2026 was $5.35 Mil. Gain Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $19.70 Mil.

Gain Therapeutics Total Operating Expense Related Terms

Gain Therapeutics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Gain Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gain Therapeutics Total Operating Expense Chart

Gain Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial 13.99 17.92 22.31 20.35 18.71

Gain Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.37 5.09 4.79 4.47 5.35
GANX
32GF Score
Gain Therapeutics Inc GANX
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gain Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $19.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $19.70 Mil mean?
Gain Therapeutics (GANX) has a Total Operating Expense of $19.70 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Gain Therapeutics and its competitors.
Is Gain Therapeutics' Total Operating Expense too high?
Gain Therapeutics' current Total Operating Expense is $19.70 Mil. Overall, Gain Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Gain Therapeutics' Total Operating Expense compare to HYFT and ELTX?
Gain Therapeutics' Total Operating Expense of $19.70 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Gain Therapeutics and its competitors. Gain Therapeutics's current Total Operating Expense is $19.70 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gain Therapeutics stock overvalued right now?
Gain Therapeutics (GANX) has a current Total Operating Expense of $19.70 Mil. The current Total Operating Expense is $19.70 Mil. Gain Therapeutics' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Gain Therapeutics (GANX), the current Total Operating Expense is $19.70 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gain Therapeutics Business Description

Address 4800 Montgomery Lane, Suite 220, Bethesda, MD, USA, 20814
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
32GF Score

Get the complete analysis for GANX

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.91
Price